Healthcare bankers are in high demand in an ‘extremely, extremely active’ hiring market. Here’s a rundown of 18 dealmaker moves.

Healthcare bankers are in high demand in an ‘extremely, extremely active’ hiring market. Here’s a rundown of 18 dealmaker moves.

  • Healthcare investment bankers are in high demand, and many rainmakers are on the move. 
  • Firms like SVB Leerink, JPMorgan, and Deutsche Bank are all hiring away top talent.
  • Insider is tracking all of the big moves in the healthcare banking world.
  • See more stories on Insider’s business page.

Healthcare deals have been off to a brisk start this year, making bankers in the space some of the hottest commodities on Wall Street. 

Year to date, more than 1,860 healthcare deals have been announced, according to Refinitiv data. The first quarter alone saw 1,304 of those deals, making it the second-highest quarter on record for healthcare deals by number of transactions.

And the frantic dealmaking has led to a war for talent.

Charles Anderson, who leads Heidrick & Struggles’ corporate- and investment-banking recruiting business, described the demand from clients for healthcare searches as being “extremely, extremely active” in recent months.

Much of the momentum in the sector, he said, has been driven by demand for specialists who can help companies at the intersection of healthcare and other tech verticals, such as payment technology.

Anderson’s firm, which handles mostly senior-level placements, has been looking for bankers specializing in biotech, pharma, financial sponsors, and mergers-and-acquisitions work in healthcare.

But it’s not just senior bankers who are in demand. There’s a need for more hands on deck on the junior side, too.

“We can barely keep up,” Nick Richitt, global cohead of healthcare investment banking at Deutsche Bank, told Insider. “We’re trying to double our junior-banker population by end of summer in anticipation of deal activity.”

Some of the most active sectors in the market right now are digital and health tech, pharma services and diagnostics, and primary care, he said. Also driving the flurry of recent deals has been intense activity from the private-equity sector, Richitt added.

Deutsche Bank advised on the sale of the care-coordination software company PatientPing in April to Appriss Health, which valued the company at more than $500 million. The bank also worked on the initial public offering in April of Agilon Health, which works with physicians on payment and care delivery for seniors.

The year has also had some megadeals in healthcare, including Thermo Fisher Scientific’s announced acquisition of PPD, a clinical-research and laboratory-services company, in April for more than $17 billion cash plus $3.5 billion in net debt. Barclays and Morgan Stanley advised Thermo Fisher Scientific, while JPMorgan Securities advised PPD.

The next month Ginkgo Bioworks Inc. and the Soaring Eagle Acquisition Corp. special-purpose acquisition company announced a merger in a deal worth $17.5 billion.

The equity-capital-markets side has had 514 issuances (including IPOs, follow-ons, and equity-related proceeds) that have generated more than $72.5 billion in 2021. That’s compared to 1,143 last year that generated $170 billion, according to Refinitiv.

Some midsize firms have made progress in healthcare ECM

The heavy hitters advising on 2021 healthcare M&A deals have included Goldman Sachs, which topped a 2021 league table from Dealogic, followed by JPMorgan, Morgan Stanley, Barclays, Citi, Allen & Co., and Bank of America Securities.

But the space isn’t dominated just by Wall Street’s biggest names.

Several boutique firms followed BofA Securities in the rankings, including Centerview Partners and Guggenheim Securities.

On the ECM side, SVB Leerink, a Boston-based subsidiary of SVB Financial Group that has been making waves lately for a series of senior-level hires, is an outsized player.

The bank ranked fourth, behind Goldman Sachs, JPMorgan, and Bank of America, for equity-capital-markets advisory work this year, beating out Morgan Stanley and Jefferies, which ranked fifth and sixth, respectively, according to Dealogic.

SVB announced earlier in May that it had hired Anurag Jindal, formerly a managing director in healthcare investment banking at Bank of America who is also a medical doctor. Previously Jindal also spent time as the deputy head of pharma M&A in the pharma-strategy group at the Swiss pharmaceutical company Novartis.

At SVB Leerink, Jindal has come aboard as a senior managing director on the firm’s biopharma team.

According to Anderson, the recruiter, a “handful” of midsize firms with strong equity-research and ECM capabilities “have been able to leverage those capabilities and good bankers to do an enormous amount of ECM deals in the emerging growth/biotech space, which is a very hot space.” 

“It’s relatively profitable. It’s super high-volume, dozens of deals a year, whereas other boutiques that are more focused on M&A — there’s just far less deal flow,” he added.

Much of those banks’ appeal to clients, Anderson said, comes from companies in the biotech sector.

Biotech firms might be interested in pursuing a public offering in the short term or at some point down the line, he said, and being able to turn to a bank that has a full suite of equity-research capabilities is a plus.

Healthcare bankers are in demand, but there isn’t an endless supply of the right talent

In healthcare investment banking, especially in bio-pharmaceuticals and life sciences, the work is nuanced and requires a strong working knowledge of complicated concepts in healthcare and medical science, Anderson said. 

That means the typical talent pool, particularly at the senior level, is relatively limited. 

“There’s a lot of medical doctors that are in investment banking, covering biotech and biopharma,” Anderson said.

But as tech bankers become increasingly focused on specific niches, more software dealmakers with a knowledge of healthcare IT are making inroads, Anderson said.

As a result, a number of top dealmakers have been on the move in recent months, as some bulge-bracket banks have ceded talent to smaller operations like SVB Leerink.

We’ve been following the comings and goings of some of Wall Street’s most in-demand healthcare bankers.

With poaching among big banks, a wave of hires by smaller shops, and even some people jumping to work at

healthcare companies
themselves, we’ve got the details on where senior dealmakers have departed lately and where they’ve ended up.


Jon Swope

Previous firm: Bank of America

Previous role: Managing director in the global healthcare investment banking group

When their move was announced: June 21

Where they’re going: SVB Leerink

What they’re doing now: Managing director in healthcare investment banking focused on healthtech and digital health 

Swope will be based in New York and will report to healthcare investment banking head Barry Blake, SVB Leerink said in a press release


Ryan Kaeding

Previous firm: Piper Sandler

Previous role: Director

When their move was announced: June 8

Where they’re going: Raymond James

What they’re doing now: Managing director in MedTech

Kaeding will be based in Los Angeles and focus on advising clients in the medical devices space, Raymond James said in a press release. He brings experience from having advised on more than 65 MedTech transactions, the company added.


Bob Jackey

Previous role: Managing director in healthcare services, Citigroup

When their move was announced: June 16

Where they’re going: SVB Leerink

What they’re doing now: Managing director in healthcare services

SVB Leerink said in a press release that hiring Jackey will help “serve to expand SVB Leerink’s expertise in life sciences and healthcare technology.” Jackey will be based in New York and report to Barry Blake, global co-head of healthcare investment banking.


Chuck Adams

Adams, Chuck

Chuck Adams

Citi


Previous firm: Goldman Sachs

Previous role: Partner

When their move was announced: June 2, 2021

Where they’re going: Citigroup

What they’re doing now: Vice chairman and global head of the newly-formed global healthcare, consumer & wellness “super group,” according to an internal memo reviewed by Insider.


Dino Dedić

Dino Dedic _ Guggenheim



Courtesy of Guggenheim Securities


Previous firm: Barclays

Previous role: Managing director in global healthcare banking

When their move was announced: May 17, 2021

Where they’re going: Guggenheim Securities

What they’re doing now: Senior managing director in healthcare investment banking, focusing on advising clients in pharmaceuticals and animal health, the firm said.


Christopher Gartin

1519346870095

Christopher Gartin.

LinkedIn


Previous firm: Citigroup

Previous role: Managing director for healthcare investment banking

When their move was announced: May 21

Where they’re going: JPMorgan

What they’re doing now: Managing director for healthcare investment banking

Previously, Gartin has worked on deals for healthcare clients like Celgene Corp. in its $74 billion sale to Bristol Myers Squibb in 2019, Bloomberg reported.


Anurag Jindal

Previous firm: Bank of America

Previous role: Managing director in the healthcare-banking group, with a focus on the biotech sector 

When their move was announced: May 20

Where they’re going: SVB Leerink

What they’re doing now: Senior managing director on the biopharma team


M. Toby King

Previous firm: Citi

Previous Role: Managing director and head of North America healthcare

When their move was announced: May 18

Where they’re going: SVB Leerink

What they’re doing now: Senior managing director in healthcare services


Priyanka Verma

Priya120521

Priyanka Verma.

Deutsche Bank


Previous firm: HSBC

Previous Role: Managing director of healthcare investment banking

When their move was announced: May 13

Where they’re going: Deutsche Bank

What they’re doing now: Managing director and Americas head of pharma services and diagnostics division


Richard Singh

Singh_Richard_Colorprint2021.JPG

Richard Singh.

Piper Sandler


Previous firm: Gleacher Shacklock

Previous role: Partner

When their move was announced: May 11

Where they’re going: Piper Sandler

What they’re doing now: Managing director in healthcare investment banking

Singh will be based in London, the company said in a press release, adding that his addition reflects the firm’s “European healthcare investment banking growth strategy.”


Jack Bannister

Jack Bannister

Jack Bannister.

SVB Leerink


Previous firm: Goldman Sachs

Previous role: Vice president of the healthcare equity-capital-markets team

When their move was announced: April 8

Where they’re going: SVB Leerink

What they’re doing now: Managing director on the equity-capital-markets team, focusing on healthcare and life-sciences companies


Ben Carpenter

Previous firm: Citi

Previous role: Global head of life-sciences M&A

When their move was announced: April 7

Where they’re going: JPMorgan

What they’re doing now: Cohead of healthcare M&A

In his new role at JPMorgan, Carpenter will help supervise deals focusing on biopharmaceuticals, Bloomberg reported in April, citing an internal JPMorgan memo.


Paul Tomasic

PT Photo April2 1

Paul Tomasic.

Houlihan Lokey


Previous firm: RBC Capital Markets

Previous role: Managing director and head of European healthcare

When their move was announced: April 7

Where they’re going: Houlihan Lokey

What they’re doing now: Managing director and head of European healthcare


Andrew Fineberg

Andrew Fineberg

Andrew Fineberg.

SVB Leerink


Previous firm: MTS Health Partners

Previous role: Partner and head of royalty monetization services

When their move was announced: April 6

Where they’re going: SVB Leerink

What they’re doing now: Managing director of structured finance

Fineberg advises corporate, academic, and medical nonprofit institutions on royalty monetization and private credit, according to his official company bio.


Thaddeus Davis

Thad Davis

Thaddeus Davis.

SVB Leerink


Previous firm: HSBC

Previous role: Head of US healthcare investment banking

When their move was announced: April 1

Where they’re going: SVB Leerink

What they’re doing now: Senior managing director, leveraged finance


Barry Blake

Barry Blake

Barry Blake.

SVB Leerink


Previous firm: Guggenheim Securities

Previous role: Senior managing director focused on advising healthcare-services companies

When their move was announced: February 16

Where they’re going: SVB Leerink

What they’re doing now: Global cohead of investment banking


Charlie Newton

1592751671936 1

Charlie Newton.

LinkedIn


Previous firm: Bank of America

Previous role: Cohead of healthcare investment banking in the Americas

When their move was announced: February 9

Where they’re going: Lyell Immunopharma

What they’re doing now: Chief financial officer


Jeffrey Thomas

Previous firm: Laborie

Previous role: Chief corporate-development officer

When their move was announced: May 28

Where they’re going: Piper Sandler

What they’re doing now: Managing director in healthcare investment banking, covering medtech and life-sciences tools and diagnostics


Did we miss someone? Share news and tips with Samantha Stokes at sstokes@insider.com, on Signal at 646-389-7866, or direct message on Twitter @stokessamanthaj. Contact Reed Alexander at ralexander@insider.com, on Signal at 561-247-5758, or direct message on Twitter @reedalexander.

https://ragheadnews.com

Leave a Reply

Your email address will not be published. Required fields are marked *